{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:28:40Z","timestamp":1788571720770,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Diffusing alpha-emitters Radiation Therapy (\u201cAlpha DaRT\u201d) is a new cancer treatment modality that employs radium-224-loaded metal sources implanted in solid tumors to disperse alpha-emitting atoms within a therapeutic \u201ckill-zone\u201d of a few millimeters around each source. Preclinical studies have demonstrated tumor growth delay in various cancer types, including glioblastoma multiforme, and the method is used in clinical trials for patients with skin and head and neck cancer. This study aims to assess the safety and feasibility of implementing Alpha DaRT for brain tumor treatment in a large animal model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Alpha-DaRT sources were delivered via image-guided stereotactic implantation into both hemispheres of eight swine. 1\u20133 layers of radial deployment of 7 sources were delivered through a single penetration point into each hemisphere. A 90-day follow-up period included clinical evaluation, brain MRI, head CT, blood, CSF, urine, and feces sampling, and an analysis of source location over time. Brain tissue pathology was performed on termination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Alpha-DaRT sources were reproducibly and efficiently delivered to the brain cortex and subcortex. No unexpected abnormalities were detected in blood or CSF samples. MRI and CT scans revealed no evidence of major bleeding or infection. Measurements of <jats:sup>212<\/jats:sup>Pb in blood and CSF exhibited the expected exponential decay from day 7 to day 14 post-source implantation. Minimal spatial and temporal movements of the sources were noted. Histopathological analysis demonstrated locally confined findings in brain parenchyma in a very close proximity to the sources.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Alpha<jats:bold>-<\/jats:bold>DaRT sources can be safely delivered into a large animal brain using image-guided stereotactic implantation. These findings support further exploration of Alpha DaRT as a potential treatment modality for brain tumors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-024-04919-5","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:38:20Z","timestamp":1735868300000},"page":"387-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors"],"prefix":"10.1007","volume":"172","author":[{"given":"Yigal","family":"Shoshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe J.","family":"Gomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem Eben","family":"Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Edery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Den","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Arazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Popovtzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Moscovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"4919_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","volume":"18","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2009\u20132013. Neuro Oncol 18:v1\u2013v75. https:\/\/doi.org\/10.1093\/neuonc\/now207","journal-title":"Neuro Oncol"},{"key":"4919_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba N, Wen PY, Aizer AA (2021) Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol 23:1447\u20131456. https:\/\/doi.org\/10.1093\/neuonc\/noab101","journal-title":"Neuro Oncol"},{"key":"4919_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","volume":"149","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Wright CH, Barnholtz-Sloan JS (2018) Brain metastases: epidemiology. Handb Clin Neurol 149:27\u201342. https:\/\/doi.org\/10.1016\/B978-0-12-811161-1.00002-5","journal-title":"Handb Clin Neurol"},{"key":"4919_CR4","first-page":"1","volume":"68","author":"M Heron","year":"2019","unstructured":"Heron M (2019) Deaths: leading causes for 2017. Natl Vital Stat Rep 68:1\u201377","journal-title":"Natl Vital Stat Rep"},{"key":"4919_CR5","doi-asserted-by":"publisher","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987\u2013996 https:\/\/doi.org\/10.1056\/NEJMoa043330","DOI":"10.1056\/NEJMoa043330"},{"key":"4919_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/rpd\/ncy300","volume":"183","author":"JM Thompson","year":"2019","unstructured":"Thompson JM, Elliott A, D\u2019Abrantes S, Sawakuchi GO, Hill MA (2019) Tracking down Alpha-Particles: the design, Characterisation and Testing of a shallow-angled alpha-particle irradiator. Radiat Prot Dosimetry 183:264\u2013269. https:\/\/doi.org\/10.1093\/rpd\/ncy300","journal-title":"Radiat Prot Dosimetry"},{"key":"4919_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fonc.2020.00082","volume":"10","author":"TD Malouff","year":"2020","unstructured":"Malouff TD, Mahajan A, Krishnan S, Beltran C, Seneviratne DS, Trifiletti DM (2020) Carbon Ion Therapy: a modern review of an Emerging Technology. Front Oncol 10:82. https:\/\/doi.org\/10.3389\/fonc.2020.00082","journal-title":"Front Oncol"},{"key":"4919_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09553006614550421","volume":"10","author":"GW Barendsen","year":"1966","unstructured":"Barendsen GW, Koot CJ, Van Kersen GR, Bewley DK, Field SB, Parnell CJ (1966) The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol Relat Stud Phys Chem Med 10:317\u2013327. https:\/\/doi.org\/10.1080\/09553006614550421","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"4919_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2307\/3573591","volume":"52","author":"EJ Hall","year":"1972","unstructured":"Hall EJ, Gross W, Dvorak RF, Kellerer AM, Rossi HH (1972) Survival curves and age response functions for Chinese hamster cells exposed to x-rays or high LET alpha-particles. Radiat Res 52:88\u201398","journal-title":"Radiat Res"},{"key":"4919_CR10","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1089\/ars.2013.5378","volume":"21","author":"JC Walsh","year":"2014","unstructured":"Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC (2014) The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal 21:1516\u20131554. https:\/\/doi.org\/10.1089\/ars.2013.5378","journal-title":"Antioxid Redox Signal"},{"key":"4919_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcancer.2021.04.021","volume":"78","author":"S Basu","year":"2022","unstructured":"Basu S, Dong Y, Kumar R, Jeter C, Tang DG (2022) Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis. Semin Cancer Biol 78:90\u2013103. https:\/\/doi.org\/10.1016\/j.semcancer.2021.04.021","journal-title":"Semin Cancer Biol"},{"key":"4919_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-bioeng-062117-120931","volume":"20","author":"MR McDevitt","year":"2018","unstructured":"McDevitt MR, Sgouros G, Sofou S (2018) Targeted and nontargeted alpha-particle therapies. Annu Rev Biomed Eng 20:73\u201393. https:\/\/doi.org\/10.1146\/annurev-bioeng-062117-120931","journal-title":"Annu Rev Biomed Eng"},{"key":"4919_CR13","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"TAT Working","year":"2018","unstructured":"Working TAT, Parker G, Lewington C, Shore V, Kratochwil N, Levy C, Linden M, Noordzij O, Park W, Saad J F (2018) Targeted alpha therapy, an emerging class of Cancer agents: a review. JAMA Oncol 4:1765\u20131772. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4044","journal-title":"JAMA Oncol"},{"key":"4919_CR14","doi-asserted-by":"publisher","unstructured":"Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G, Khushalani NI, Moros EG, McLaughlin ML, Wadas TJ, Morse DL (2019) Development of targeted alpha particle therapy for solid tumors. Molecules 24. https:\/\/doi.org\/10.3390\/molecules24234314","DOI":"10.3390\/molecules24234314"},{"key":"4919_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40265-014-0198-4","volume":"74","author":"M Shirley","year":"2014","unstructured":"Shirley M, McCormack PL (2014) Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs 74:579\u2013586. https:\/\/doi.org\/10.1007\/s40265-014-0198-4","journal-title":"Drugs"},{"key":"4919_CR16","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1088\/0031-9155\/52\/16\/021","volume":"52","author":"L Arazi","year":"2007","unstructured":"Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I (2007) Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol 52:5025\u20135042. https:\/\/doi.org\/10.1088\/0031-9155\/52\/16\/021","journal-title":"Phys Med Biol"},{"key":"4919_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/ijc.23268","volume":"122","author":"T Cooks","year":"2008","unstructured":"Cooks T, Arazi L, Schmidt M, Marshak G, Kelson I, Keisari Y (2008) Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms. Int J Cancer 122:1657\u20131664. https:\/\/doi.org\/10.1002\/ijc.23268","journal-title":"Int J Cancer"},{"key":"4919_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ijrobp.2009.02.063","volume":"74","author":"T Cooks","year":"2009","unstructured":"Cooks T, Schmidt M, Bittan H, Lazarov E, Arazi L, Kelson I, Keisari Y (2009) Local control of lung derived tumors by diffusing alpha-emitting atoms released from intratumoral wires loaded with radium-224. Int J Radiat Oncol Biol Phys 74:966\u2013973. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.063","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4919_CR19","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.24191","volume":"115","author":"T Cooks","year":"2009","unstructured":"Cooks T, Arazi L, Efrati M, Schmidt M, Marshak G, Kelson I, Keisari Y (2009) Interstitial wires releasing diffusing alpha emitters combined with chemotherapy improved local tumor control and survival in squamous cell carcinoma-bearing mice. Cancer 115:1791\u20131801. https:\/\/doi.org\/10.1002\/cncr.24191","journal-title":"Cancer"},{"key":"4919_CR20","first-page":"5315","volume":"32","author":"T Cooks","year":"2012","unstructured":"Cooks T, Tal M, Raab S, Efrati M, Reitkopf S, Lazarov E, Etzyoni R, Schmidt M, Arazi L, Kelson I, Keisari Y (2012) Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control. Anticancer Res 32:5315\u20135321","journal-title":"Anticancer Res"},{"key":"4919_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trsl.2011.08.009","volume":"159","author":"G Horev-Drori","year":"2012","unstructured":"Horev-Drori G, Cooks T, Bittan H, Lazarov E, Schmidt M, Arazi L, Efrati M, Kelson I, Keisari Y (2012) Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms. Transl Res 159:32\u201341. https:\/\/doi.org\/10.1016\/j.trsl.2011.08.009","journal-title":"Transl Res"},{"key":"4919_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-013-1462-2","volume":"63","author":"Y Keisari","year":"2014","unstructured":"Keisari Y, Hochman I, Confino H, Korenstein R, Kelson I (2014) Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments. Cancer Immunol Immunother 63:1\u20139. https:\/\/doi.org\/10.1007\/s00262-013-1462-2","journal-title":"Cancer Immunol Immunother"},{"key":"4919_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-016-1878-6","volume":"65","author":"H Confino","year":"2016","unstructured":"Confino H, Schmidt M, Efrati M, Hochman I, Umansky V, Kelson I, Keisari Y (2016) Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. Cancer Immunol Immunother 65:1149\u20131158. https:\/\/doi.org\/10.1007\/s00262-016-1878-6","journal-title":"Cancer Immunol Immunother"},{"key":"4919_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.10.048","author":"A Popovtzer","year":"2019","unstructured":"Popovtzer A, Rosenfeld E, Mizrachi A, Bellia SR, Ben-Hur R, Feliciani G, Sarnelli A, Arazi L, Deutsch L, Kelson I, Keisari Y (2019) Initial Safety and Tumor Control Results from a first-in-human multicenter prospective trial evaluating a Novel Alpha-Emitting Radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and Head and Neck. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.048","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4919_CR25","doi-asserted-by":"publisher","first-page":"e2312824","DOI":"10.1001\/jamanetworkopen.2023.12824","volume":"6","author":"MA D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea MA, VanderWalde NA, Ballo MT, Patra P, Cohen GN, Damato AL, Barker CA (2023) Feasibility and safety of Diffusing Alpha-Emitter Radiation Therapy for recurrent or unresectable skin cancers. JAMA Netw Open 6:e2312824. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.12824","journal-title":"JAMA Netw Open"},{"key":"4919_CR26","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/mp.16145","volume":"50","author":"G Heger","year":"2023","unstructured":"Heger G, Roy A, Dumancic M, Arazi L (2023) Alpha dose modeling in diffusing alpha-emitters radiation therapy-part I: single-seed calculations in one and two dimensions. Med Phys 50:1793\u20131811. https:\/\/doi.org\/10.1002\/mp.16145","journal-title":"Med Phys"},{"key":"4919_CR27","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/mp.16155","volume":"50","author":"G Heger","year":"2023","unstructured":"Heger G, Dumancic M, Roy A, Arazi L (2023) Alpha dose modeling in diffusing alpha-emitters radiation therapy. Part II: lattice studies. Med Phys 50:1812\u20131823. https:\/\/doi.org\/10.1002\/mp.16155","journal-title":"Med Phys"},{"key":"4919_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1088\/0031-9155\/55\/4\/020","volume":"55","author":"L Arazi","year":"2010","unstructured":"Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I (2010) The treatment of solid tumors by alpha emitters released from (224)Ra-loaded sources-internal dosimetry analysis. Phys Med Biol 55:1203\u20131218. https:\/\/doi.org\/10.1088\/0031-9155\/55\/4\/020","journal-title":"Phys Med Biol"},{"key":"4919_CR29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bahr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M (2020) Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 Randomized Clinical Trial. JAMA Oncol 6:1003\u20131010. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04919-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04919-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04919-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T15:19:29Z","timestamp":1743175169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04919-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4919"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04919-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YS serves as a paid medical advisor for Alpha Tau Medical Ltd. and receives equity. AP serves as a medical advisor for Alpha Tau Medical Ltd. and receives equity. RBD serves as CMO of Alpha Tau Medical Ltd. and receives compensation and equity. LA receives equity and has a research budget funded by the company. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}